Mesoblast partners with BMT CTN

Mesoblast announced that the Blood and Marrow Transplant Clinical Trials Network, a body including centers responsible for approximately 80% of all U.S. allogeneic BMTs, has entered into an agreement to develop a pivotal trial of Mesoblast’s lead product candidate Ryoncil in the treatment of adults with steroid-refractory acute graft versus host disease. The BMT CTN is funded by the United States National Institutes of Health.